FOLD - Amicus Therapeutics, Inc.
| Previous Close | 9.35 |
| Open | 9.41 |
| Bid | 9.02 x 4000 |
| Ask | 9.80 x 1100 |
| Day's Range | 9.28 - 9.68 |
| 52 Week Range | 7.11 - 14.62 |
| Volume | 3,092,093 |
| Avg. Volume | 3,702,756 |
| Market Cap | 2.44B |
| Beta (3Y Monthly) | 1.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates
3Q19 Galafold® (migalastat) Revenue of $48.8M and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue.
- GlobeNewswire
Amicus Therapeutics to Announce Third Quarter 2019 Financial Results on November 11, 2019
CRANBURY, N.J., Oct. 30, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11,.
- GlobeNewswire
Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Society
Amicus Therapeutics (FOLD) today announced additional positive interim results from its CLN6 Batten disease gene therapy program licensed from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital. The results are featured in a poster presentation at the 48th Annual Meeting of the Child Neurology Society to be held October 23-26, 2019 in Charlotte, NC.
- GlobeNewswire
Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day
Amicus Therapeutics (FOLD) today announced preliminary unaudited revenue for the third quarter of 2019 in advance of its Analyst Day, to be held today, October 10, 2019, in New York City at 8:30 a.m. Today’s Analyst Day will highlight the financial strength and outlook of the Company in addition to recent progress and updates related to its early- and late-stage rare disease portfolio, including a late-stage biologic AT-GAA with breakthrough therapy designation (BTD) for Pompe disease, a clinical-stage intrathecal AAV gene therapy with positive interim results in CLN6 Batten disease, and a robust gene therapy pipeline. The live event will be audio webcasted simultaneously and accessible via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events-and-presentations, and will be archived for 90 days.
- GlobeNewswire
Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society
Amicus Therapeutics (FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in adult patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells. The U.S. Food and Drug Administration (FDA) previously granted Breakthrough Therapy Designation (“BTD”) to AT-GAA for the treatment of late onset Pompe disease based on clinical efficacy results this Phase 1/2 clinical study, including improvements in six-minute walk distance in late onset Pompe patients and comparison to natural history of treated patients.
- GlobeNewswire
Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019
CRANBURY, N.J., Oct. 01, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following medical and investor conferences in October..
- GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019
CRANBURY, N.J., Sept. 04, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September. Bradley.
- GlobeNewswire
Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates
2Q19 Galafold® (migalastat) Revenue of $44.1M Represents Highest Quarterly Growth Since Launch Driven by Continued Strong Global Uptake Reiterating FY19 Revenue.
- GlobeNewswire
Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina
Amicus Therapeutics (FOLD) today announced that the Agency of Medicines, Food and Medical Devices (ANMAT) in Argentina has granted approval for the first-in-class, oral small molecule pharmacological chaperone Galafold® (migalastat), as a monotherapy for the treatment of people aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. Galafold® is the first and only oral precision medicine for Fabry disease approved in Argentina.
- GlobeNewswire
Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease
Amicus Therapeutics (FOLD) today announced positive interim results from its CLN6 Batten disease gene therapy program licensed from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital. AWRI is conducting the ongoing Phase 1/2 clinical study of a single one-time intrathecal administration of AAV-CLN6 gene therapy for CLN6 Batten disease.
- GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
CRANBURY, N.J., July 29, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8,.
- GlobeNewswire
Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing
Supports Clinical and Commercial Supply Needs for Pompe and Other Lysosomal Disease Gene Therapy Programs Advances Amicus’ Mission to Deliver Novel Gene Therapies to Rare.
- GlobeNewswire
Amicus Therapeutics and Brammer Bio, a part of Thermo Fisher Scientific, Enter Strategic Gene Therapy Development and Manufacturing Collaboration
Amicus Therapeutics, Inc. (FOLD) has entered into a strategic manufacturing collaboration with Thermo Fisher Scientific1. Thermo Fisher, a best-in-class contract development and manufacturing organization (CDMO) with late-stage clinical and commercial-scale capabilities provides Amicus with immediate clinical and commercial manufacturing capabilities and capacity for the Amicus intrathecal AAV Batten disease gene therapy programs.
- GlobeNewswire
Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership
Amicus Therapeutics (FOLD) today announced two new additions to the Senior Leadership Team. Jill Weimer, PhD, a developmental neuroscientist and recognized thought leader in the field of neurologic rare disease gene therapy science, has joined as Senior Vice President of Discovery Research and Gene Therapy Science.
- GlobeNewswire
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
CRANBURY, N.J., June 04, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total.
- GlobeNewswire
Amicus Therapeutics to Present at Upcoming Scientific and Investor Conferences
CRANBURY, N.J., June 03, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following scientific and investor conferences in June..
- GlobeNewswire
Amicus Therapeutics Prices Underwritten Offering of Common Stock
Amicus Therapeutics (FOLD) today announced the pricing of an underwritten offering of 16,279,070 shares of its common stock at $10.75 per share. The gross proceeds from the offering to Amicus are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,441,860 shares of its common stock.
- GlobeNewswire
Amicus Therapeutics Announces Public Offering of Common Stock
Amicus Therapeutics (FOLD) today announced it has commenced a $150 million underwritten public offering of its common stock. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint book-running managers for the proposed offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.
- GlobeNewswire
Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration
Exclusive Disease-Specific Worldwide Rights to Penn’s Next Generation Gene Therapy Technologies from the Wilson Lab for the Majority of Lysosomal Disorders Current.
- GlobeNewswire
Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors
Amicus Therapeutics (FOLD) today announced the election and appointment of Burke W. Whitman to its Board of Directors, effective at the end of this quarter. Mr. Whitman is a proven leader of corporate and military organizations. He has served as a corporate CEO, CFO and board member of multiple publicly-traded and Fortune 500 healthcare service companies, as well as the commanding general of the 4th Marine Division and the commander of Marine Forces Reserve. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “On behalf of our Board of Directors, I am pleased to announce Burke Whitman’s appointment to the Amicus Board.
- GlobeNewswire
Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
CRANBURY, N.J., May 10, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside.
- GlobeNewswire
Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates
1Q19 Galafold® (migalastat) Strong Launch Trends Continue with Largest Quarterly Number of Net New Patients Added Globally (150+ Net New Galafold Patients in 1Q19) 1Q19.
- GlobeNewswire
Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
Amicus Therapeutics (FOLD) today announced initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in mice. Pompe disease is an inherited lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA).
- GlobeNewswire
Amicus Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
CRANBURY, N.J., April 25, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 8,.
- GlobeNewswire
Amicus Therapeutics to Present Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
CRANBURY, N.J., April 15, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced the company will present initial preclinical data from its investigational adeno-associated.